Anika Therapeutics (NASDAQ:ANIK - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $27.03 million for the quarter.
Anika Therapeutics Stock Up 1.7%
ANIK stock traded up $0.19 during trading on Friday, hitting $11.50. 55,525 shares of the company's stock traded hands, compared to its average volume of 123,009. The firm has a market capitalization of $164.91 million, a P/E ratio of -2.96 and a beta of 0.64. The business has a fifty day simple moving average of $11.21 and a two-hundred day simple moving average of $14.08. Anika Therapeutics has a 1 year low of $10.47 and a 1 year high of $28.58.
Analyst Ratings Changes
ANIK has been the subject of several research reports. B. Riley began coverage on shares of Anika Therapeutics in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Barrington Research cut their price objective on shares of Anika Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Monday, May 12th. Finally, Wall Street Zen cut shares of Anika Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 12th.
Check Out Our Latest Stock Report on ANIK
Institutional Investors Weigh In On Anika Therapeutics
A hedge fund recently bought a new stake in Anika Therapeutics stock. AQR Capital Management LLC acquired a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 12,057 shares of the biotechnology company's stock, valued at approximately $181,000. AQR Capital Management LLC owned about 0.08% of Anika Therapeutics as of its most recent filing with the SEC. 91.53% of the stock is currently owned by hedge funds and other institutional investors.
Anika Therapeutics Company Profile
(
Get Free Report)
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Featured Stories
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access